SPCC (Sharing Progress in Cancer Care) posted on LinkedIn:
“Last week in Barcelona for the Definitive Trial Annual Meeting!
This groundbreaking clinical trial, funded by the European Commission, is redefining the approach to early-stage HER2+ breast cancer.
The project aims to:
- Enhance patient’s quality of life without compromising survival or outcomes
- Demonstrate the safety and efficiency of HER2DX
- Reduce costs for hospitals and public health systems
With a consortium of 18 partners from 9 different countries, the DEFINITIVE project exemplifies collaboration and innovation at a European scale.
As one of the partners, SPCC will soon launch training sessions for health professionals: stay tuned for updates!